Recommendations for Artificial Intelligence Application in Continued Process Verification: A Journey Toward the Challenges and Benefits of AI in the Biopharmaceutical Industry

References

1. 1.↵
   U.S. Food and Drug Administration, Guidance for Industry: Process Validation: General Principles and Practices. Center for Biologics Evaluation and Research. U.S. Department of Health and Human Services: Rockville, MD, 2011.
2. 2.↵
   1. Philip A.,
   2. Shahiwala A.,
   3. Rashid M.,
   4. Faiyazuddin Md.

   1. Manzano T.,
   2. Whitford W.

   AI Applications for Multivariate Control in Drug Manufacturing. In A Handbook of Artificial Intelligence in Drug Delivery; Philip A., Shahiwala A., Rashid M., Faiyazuddin Md., Eds.; Academic Press, 2023; pp 55–82.
3. 3.↵
   1. Ondracka A.,
   2. Gasset A.,
   3. García-Ortega X.,
   4. Hubmayr D.,
   5. van Wijngaarden J.,
   6. Montesinos-Seguí J. L.,
   7. Valero F.,
   8. Manzano T.

   CPV of the Future: AI-Powered Continued Process Verification for Bioreactor Processes. PDA J. Pharm. Sci. Technol. 2023, 77 (3), 146–165.

   OpenUrlAbstract/FREE Full Text
4. 4.↵
   Parenteral Drug Association Inc. Technical Report No. 60: Process Validation: A Lifecycle Approach; Bethesda, 2013.
5. 5.↵
   1. Kim E. J.,
   2. Kim J. H.,
   3. Kim M.-S.,
   4. Jeong S. H.,
   5. Choi D. H.

   Process Analytical Technology Tools for Monitoring Pharmaceutical Unit Operations: A Control Strategy for Continuous Process Verification. Pharmaceutics 2021, 13 (6), 919.

   OpenUrlPubMed
6. 6.↵
   1. Kumar S. H.,
   2. Talasila D.,
   3. Gowrav M. P.,
   4. Gangadharappa H. V.

   Adaptations of Pharma 4.0 from Industry 4.0. Drug Invention Today 2020, 14 (3), 405.

   OpenUrl
7. 7.↵
   International Conference for Harmonisation, Quality Guideline Q8(R2): Pharmaceutical Development. ICH: Geneva, 2009.
8. 8.↵
   European Medicines Agency, Guideline on Process Validation for Finished Products—Information and Data to Be Provided in Regulatory Submissions; EMA/CHMP/CVMP/QWP/749073/2016; EMA: London, 2016.
9. 9.↵
   1. Zhang F.,
   2. Qiao Q.,
   3. Wang J.,
   4. Liu P.

   Data-Driven AI Emergency Planning in Process Industry. J. Loss Prev. Process Ind. 2022, 76, 104740.

   OpenUrl
10. 10.↵
    1. Snee R. D.

    Management Holds the Key to Continued Process Verification. Pharm. Manuf. 2015, January/February, 33–35.
11. 11.↵
    1. Masood A.,
    2. Hashmi A.

    AI Use Cases in the Industry. In Cognitive Computing Recipes; Apress: Berkeley, CA, 2019; pp 383–396.
12. 12.↵
    1. Price W. N.

    Making Do in Making Drugs: Innovation Policy and Pharmaceutical Manufacturing. Boston Coll. Law Rev. 2014, 55 (2), 491–562.

    OpenUrl
13. 13.↵
    International Conference for Harmonisation, Quality Guideline Q9: Quality Risk Management. ICH: Geneva, 2006.
14. 14.↵
    1. Smith M.,
    2. Heath Jeffery R. C.

    Addressing the challenges of artificial intelligence in medicine. Internal Medicine Journal. 2020, 50 (10).
15. 15.↵
    U.S. Food and Drug Administration, Discussion Paper: Artificial Intelligence in Drug Manufacturing. Center for Drug Evaluation and Research. U.S. Department of Health and Human Services: Rockville, MD, 2023.
16. 16.↵
    1. Anttonen E.,
    2. Begi H.,
    3. Dubs M.,
    4. Helliwell I.,
    5. Selva J.

    The Development of a Digital Plant Maturity Model to Aid Transformation in Biopharmaceutical Manufacturing, BioPhorum, 2016.
17. 17.↵
    1. Bokulich N. A.,
    2. Dillon M.,
    3. Bolyen E.,
    4. Kaehler B. D.,
    5. Huttley G. A.,
    6. Caporaso J. G.

    q2-Sample-Classifier: machine-Learning Tools for Microbiome Classification and Regression. 2018.
18. 18.↵
    1. Wang R.

    Significantly Improving the Prediction of Molecular Atomization Energies by an Ensemble of Machine Learning Algorithms and Rescanning Input Space: A Stacked Generalization Approach. J. Phys. Chem. C 2018, 122 (16), 8868–8873.

    OpenUrl
19. 19.↵
    1. Whitford B.,
    2. Manzano T.

    The Promise of AI in Gene and Cell Therapy Operations. Genet. Eng. Biotechnol. News 2022, 42 (2), 18–19.

    OpenUrl
20. 20.↵
    U.S. Food and Drug Association, 21 CFR Part 211—Current Good Manufacturing Practice for Finished Pharmaceuticals, Subpart J—Records and Reports, Section 180(e). U.S. Department of Health and Human Services. Government Publishing Office: Washington, D.C., 2005.
21. 21.↵
    1. Steinwandter V.,
    2. Borchert D.,
    3. Herwig C.

    Data Science Tools and Applications on the Way to Pharma 4.0. Drug Discovery Today. 2019, 24 (9), 1795–1805.

    OpenUrlPubMed
22. 22.
    European Medicines Agency, Guideline on Process Validation for Finished Products—Information and Data to be Provided in Regulatory Submissions; EMA/CHMP/CVMP/QWP/749073/2016; EMA: London, 2016.
23. 23.
    1. Bhattacharya A.

    Applied Machine Learning Explainability Techniques: Make ML Models Explainable and Trustworthy for Practical Applications using LIME, SHAP, and More. Packt Publishing, 2022.
24. 24.
    1. Murshid M. A.,
    2. Halim M. S. B. A.,
    3. Osman A.

    An Examination of Two Dimensions of Physician Perceived Value on Physician Satisfaction in the Yemeni Pharmaceutical Industry. Asian Soc. Sci. 2014, 10 (16), 14–26.

    OpenUrl
25. 25.
    European Medicines Agency, The use of Artificial Intelligence in the Medicinal Product Lifecycle; EMA/CHMP/CVMP/83833/2023; EMA: London, 2023.
26. 26.
    United Nations Industrial Development Organization. Empowering SMEs Through 4IR Technologies. UNIDO, 2021.
27. 27.
    1. Ribeiro M. T.,
    2. Singh S.,
    3. Guestrin C.

    "Why Should I Trust You?”. Explaining the Predictions of Any Classifier. https://doi.org/10.48550/arXiv.1602.04938.